NAV

Hybrid Between B and C Type Hemes (Protoporphyrin Ixcontaining Fe)

Identification

Generic Name
Hybrid Between B and C Type Hemes (Protoporphyrin Ixcontaining Fe)
DrugBank Accession Number
DB02182
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Similar Structures
Weight
Average: 618.503
Monoisotopic: 618.192947729
Chemical Formula
C34H34FeN4O4
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
USoluble cytochrome b562Not AvailableEscherichia coli
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
BUYPFLNIJYEQJK-RGGAHWMASA-N
InChI
InChI=1S/C34H34N4O4.Fe/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;/h8,13-16H,2,7,9-12H2,1,3-6H3,(H,39,40)(H,41,42);/q-4;+4/b25-13-,26-13-,27-14-,28-15-,29-14-,30-15-,31-16-,32-16-;
IUPAC Name
3-[20-(2-carboxyethyl)-15-ethenyl-10-ethyl-5,9,14,19-tetramethyl-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^{2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3(24),4,6,8,10,12,14,16,18,20-decaen-4-yl]propanoic acid
SMILES
CCC1=C2C=C3N4C(=CC5=C(C)C(CCC(O)=O)=C6C=C7N8C(=CC(N2[Fe]48N56)=C1C)C(C)=C7CCC(O)=O)C(C=C)=C3C

References

General References
Not Available
PubChem Compound
131704193
PubChem Substance
46508488
PDBe Ligand
HEB

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.418 mg/mLALOGPS
logP4.31ALOGPS
logP8.13Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)3.72Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area94.32 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity169.73 m3·mol-1Chemaxon
Polarizability70.45 Å3Chemaxon
Number of Rings8Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.6019
Blood Brain Barrier-0.5233
Caco-2 permeable-0.594
P-glycoprotein substrateSubstrate0.7214
P-glycoprotein inhibitor INon-inhibitor0.5689
P-glycoprotein inhibitor IINon-inhibitor0.753
Renal organic cation transporterNon-inhibitor0.8313
CYP450 2C9 substrateNon-substrate0.7562
CYP450 2D6 substrateNon-substrate0.8171
CYP450 3A4 substrateSubstrate0.5801
CYP450 1A2 substrateInhibitor0.616
CYP450 2C9 inhibitorNon-inhibitor0.7308
CYP450 2D6 inhibitorNon-inhibitor0.5742
CYP450 2C19 inhibitorNon-inhibitor0.7562
CYP450 3A4 inhibitorNon-inhibitor0.7296
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6632
Ames testNon AMES toxic0.5952
CarcinogenicityNon-carcinogens0.8656
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6702 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9279
hERG inhibition (predictor II)Non-inhibitor0.8877
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Soluble cytochrome b562
Kind
Protein
Organism
Escherichia coli
Pharmacological action
Unknown
General Function
Iron ion binding
Specific Function
Electron-transport protein of unknown function.
Gene Name
cybC
Uniprot ID
P0ABE7
Uniprot Name
Soluble cytochrome b562
Molecular Weight
14060.815 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52